You are here

JNJ

Johnson & Johnson forecasts as much as 6% sales growth in 2024

Johnson & Johnson forecasts as much as 6% sales growth in 2024

Reuters

Flag link:

J&J Hires Thousands, Invests Millions in AI-Powered Drug Discovery

J&J Hires Thousands, Invests Millions in AI-Powered Drug Discovery

BioSpace

artificial intelligence

Flag link:

J&J, AbbVie, Sanofi and many other companies face competition probe in Turkey

J&J, AbbVie, Sanofi and many other companies face competition probe in Turkey

Fierce Pharma

Flag link:

3 medtech spinoffs that reshaped the industry in 2023, and what to expect next

3 medtech spinoffs that reshaped the industry in 2023, and what to expect next

Medtech Dive

Flag link:

J&J Becomes the Newest Player in the LAA Market

J&J Becomes the Newest Player in the LAA Market

Medical Devices and Diagnostics Industry

Flag link:

Samsung Bioepis, J&J Ink Settlement and License Deal for Stelara Biosimilar

Samsung Bioepis, J&J Ink Settlement and License Deal for Stelara Biosimilar

BioSpace

Samsung Bioepsis

Flag link:

J&J Sheds Light on Plans for Surgical Robot

J&J Sheds Light on Plans for Surgical Robot

Medical Devices and Diagnostics Industry

Intuitive Surgical

robotic surgery

Flag link:

J&J Seeks Expanded Use of Lung Cancer Drug Rybrevant

J&J Seeks Expanded Use of Lung Cancer Drug Rybrevant

Yahoo/Zacks.com

non-small cell lung cancer

Flag link:

Johnson & Johnson Is Eyeing Intuitive Surgical's Market, But Can It Win?

Johnson & Johnson Is Eyeing Intuitive Surgical's Market, But Can It Win?

Motley Fool

Intuitive Surgical

robotic surgery

Flag link:

Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff

Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff

Fierce Biotech

Propella Therapeutics

prostate cancer

Flag link:

J&J and Bayer's Xarelto proves its worth across PAD subgroups in 2 new analyses

J&J and Bayer's Xarelto proves its worth across PAD subgroups in 2 new analyses

Fierce Pharma

peripheral artery disease

Flag link:

Janssen’s antibody drug shows phase 2 potential in rheumatoid arthritis

Janssen’s antibody drug shows phase 2 potential in rheumatoid arthritis

Biopharma Reporter

rheumatoid arthritis

clinical trials

Flag link:

J&J books manufacturing space at Fujifilm Diosynth's upcoming mega-plant in North Carolina

J&J books manufacturing space at Fujifilm Diosynth's upcoming mega-plant in North Carolina

Fierce Pharma

Fujifilm Diosynth Biotechnologies

Flag link:

J&J targets 2024 for Ottava FDA filing

J&J targets 2024 for Ottava FDA filing

Medtech Dive

robotic surgery

Flag link:

HHS Considers Removing J&J’s Stelara from Medicare Drug Price Negotiations

HHS Considers Removing J&J’s Stelara from Medicare Drug Price Negotiations

BioSpace

Inflation Reduction Act

Flag link:

Study of Johnson & Johnson device shows promising results for AFib

Study of Johnson & Johnson device shows promising results for AFib

Clinical Trials Arena

atrial fibrillation

Flag link:

Amgen scores FDA approval for Stelara biosimilar

Amgen scores FDA approval for Stelara biosimilar

Pharmaceutical Technology

Flag link:

GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy

GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy

Reuters

Flag link:

Cidara’s J&J-partnered immunotherapy could target flu and cancer

Cidara’s J&J-partnered immunotherapy could target flu and cancer

Pharma Voice

drug-Fc conjugates

Flag link:

Janssen reports data from Phase III trial of lung cancer drug

Janssen reports data from Phase III trial of lung cancer drug

Clinical Trials Arena

clinical trials

non-small cell lung cancer

Flag link:

Pages